Patients with Hemophilia A Benefit from Preventive Use of Newer FDA-Approved Extended Half-Life Therapies

A recent study found patients with hemophilia A experienced fewer bleeds while undergoing newer extended half-life (EHL) therapy on a prophylactic (preventive) basis. The retrospective study was conducted by AllianceRx Walgreens Prime, a leading central specialty and home delivery pharmacy, in collaboration with the...